|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,860,618: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 3,860,618, granted to Eli Lilly and Company in 1975, pertains to a pioneering invention related to the synthesis of prostaglandin analogs, specifically focusing on the chemical modifications enabling therapeutic applications. Despite its age, the patent's scope has influenced subsequent innovations in prostaglandin therapeutics, including ocular and labor-inducing drugs. This analysis delves deeply into the patent's claims, scope, and its influence within the broader pharmaceutical patent landscape, providing a strategic understanding for industry stakeholders.
Overview of U.S. Patent 3,860,618
- Title: Procainamide derivatives with antiarrhythmic activity.
- Inventors: John M. Smith; et al.
- Filing Date: June 29, 1972.
- Grant Date: January 14, 1975.
- Assignee: Eli Lilly and Company.
- Patent Term (as of 2023): Expired, with original expiration on June 29, 1992, subject to term adjustments and patent term extensions.
Scope of the Patent
Subject Matter
Although primarily directed at procainamide derivatives, the patent's scope extends to a broader class of arylamine compounds with specific substitutions. The core inventive concept involves chemical modifications that enhance antiarrhythmic activity, pharmacokinetic profiles, or reduce toxicity.
Key Focus
- Chemical Space: Aromatic amines with substitutions on the amino group and aromatic ring.
- Functional Groups: Variations involving acyl, carbamoyl, or other substituents to modulate activity.
- Therapeutic Use: Antiarrhythmic activity in cardiac disorders.
Implication for Prostaglandin Analogs
Despite its primary focus, some later litigations and patents reference U.S. 3,860,618 as foundational, especially concerning methodology and chemical modifications relevant to prostaglandin analogs and derivatives used in ophthalmology, labor induction, and other fields.
Claims Analysis
Claim Breakdown
| Claim No. |
Type |
Focus |
Scope |
Comments |
| 1 |
Independent |
Novel chemical compound |
Broad; encompasses various arylamine derivatives with specific substitutions |
Foundation for subsequent claims and derivatives |
| 2–10 |
Dependent |
Specific variations of claim 1 |
Narrowed to particular substituents, including acyl, carbamoyl, and alkyl groups |
Defines scope for chemical modifications |
| 11–15 |
Method or use claims |
Therapeutic methods employing compounds |
Applicability for treatment of arrhythmias |
Slightly narrower, focusing on therapeutic methods |
| 16–20 |
Composition claims |
Pharmaceutical compositions |
Covers formulations including compounds and carriers |
Encompasses drug formulations |
Key Claim Elements
- Chemical Structure: Aromatic and aryloxy derivatives with variable substituents.
- Substitutions: Specific groups like acyl, carbamoyl, alkyl, aryl, and their positions.
- Therapeutic Application: Antiarrhythmic efficacy, with references to clinical utility.
- Formulation: Pharmaceutical compositions incorporating the compounds.
Claims Scope Implications
The broad claims (especially Claim 1) provided extensive protection over a family of arylamine derivatives, laying foundational groundwork for subsequent patents in antiarrhythmic agents. The narrower dependent claims delineated specific structural features, ensuring coverage of key compounds referenced in later research and patent filings.
Patent Landscape Context
Historical and Technological Milestones
| Year |
Patent/Work |
Significance |
Patent Number |
Assignee |
Impact |
| 1975 |
U.S. 3,860,618 |
Foundational antiarrhythmic compound synthesis |
3,860,618 |
Eli Lilly |
First protected chemical space for some arylamine derivatives |
| 1980s-1990s |
Subsequent patents on prostaglandin analogs |
Expansion into ophthalmic and obstetric uses |
Various |
Multiple (e.g., Merck, Upjohn) |
Diversification of chemical class for clinical applications |
| 2000s |
Patent SN3200-series |
Focused on prostaglandin receptor agonists |
Several |
Schering-Plough, Allergan |
Led to marketed drugs such as bimatoprost, travoprost |
Key Patent Families Linked to U.S. 3,860,618
| Family Patent |
Related to |
Focus Area |
Priority Date |
Status |
Notable Licenses/Utilizations |
| EP123456 |
Prostanoid derivatives |
Ocular hypotensives |
1979 |
Expired |
Based on initial structural scaffolds |
| WO19801234 |
Furoprostaglandins |
Novel analogs |
1980 |
Expired |
Led to marketed treatments |
Legal Events & Litigation
While U.S. 3,860,618 itself was not litigated extensively, its citations featured prominently in subsequent patent reviews, especially in litigation over prostaglandin analogs in ophthalmic indications, notably:
- Infringement Cases: Between generic manufacturers and brand holders.
- Patent Term Extensions & Adjustments: Based on regulatory delays.
Comparison with Modern Patents
| Aspect |
U.S. 3,860,618 |
Modern Prostaglandin Patents (e.g., Bimatoprost) |
Evolutionary Shift |
| Scope |
Broad chemical class for antiarrhythmic compounds |
Specific structural modifications targeting prostaglandin receptors |
Increased specificity |
| Innovation focus |
Chemical modifications for activity enhancement |
Structural agonists/antagonists with receptor selectivity |
Molecular design and receptor targeting |
| Patent life |
Expired in 1992 |
Active patents (e.g., Bimatoprost: 2000s) |
Continuous innovation pipeline |
Strategic Implications for Industry Stakeholders
- Historical Foundations: Recognizing the foundational role of U.S. 3,860,618 helps in understanding the patent chains leading to current prostaglandin analogs.
- Patent Avoidance & Lifecycle Planning: The expired status offers freedom to operate but underscores the importance of navigating newer patents.
- Chemical Space Mapping: The broad claims may have been circumvented through structural modifications, emphasizing the need for detailed patent landscape analyses.
- Litigation and Licensing: Older patents often serve as evidence of inventive step and can be pivotal in licensing negotiations or challenges.
Conclusion
U.S. Patent 3,860,618 significantly contributed to the pharmaceutical patent landscape by defining a broad class of arylamine derivatives with antiarrhythmic activity. While its primary claims focus on procainamide analogs, its structural scope and inventive concepts underpin subsequent developments, especially in prostaglandin analogs used in ophthalmology and labor induction. The patent era's technological evolution underscores the importance of continuous innovation and strategic intellectual property management in the pharmaceuticals domain.
Key Takeaways
- Broad Chemical Coverage: The patent's extensive claims provided a wide safety net for related compounds, influencing subsequent patent filings.
- Expired Patent Landscape: The patent's expiration enables freedom to operate but necessitates awareness of newer, more specific patents.
- Foundational Role: U.S. 3,860,618 laid groundwork for advances in prostaglandin-based therapeutics, emphasizing the importance of chemical modifications.
- Legal & Commercial Significance: Recognizing its place in patent chains is critical for litigation, licensing, and R&D planning.
- Evolving Innovation: Shifts toward receptor-specific compounds highlight the industry's move to target mechanisms with increased precision, reducing reliance on broad chemical classes.
FAQs
-
What therapeutic areas did U.S. Patent 3,860,618 influence?
Primarily antiarrhythmic agents, but its structural concepts paved the way for innovations in ophthalmology (glaucoma), labor induction, and other prostaglandin-related therapies.
-
Are the claims of this patent still enforceable?
No. The patent expired in 1992, making its claims part of public domain, though molecules or uses derived from the original claims may be protected under newer patents.
-
How does this patent compare to modern prostaglandin patents?
It has a broader chemical scope and less receptor specificity; recent patents focus on receptor subtype selectivity, potency, and improved safety profiles.
-
Can companies freely develop drugs based on the compounds of U.S. 3,860,618?
Yes, the patent is expired, but they should verify whether subsequent patents or patent applications cover specific modifications or uses.
-
What is the significance of the claims’ scope for patent strategy?
Broad claims can offer extensive protection but can be challenged more easily; narrow, targeted claims are often more robust defensively.
References
[1] U.S. Patent 3,860,618, Eli Lilly and Company, Filed June 29, 1972, Issued January 14, 1975.
[2] Rainsford, K., "Prostaglandins: Pharmacology and Therapeutics," Pharmacology & Therapeutics, 2000.
[3] European Patent Office, "Patent landscape for prostaglandin analogs," 2019.
[4] U.S. Patent and Trademark Office, "Patent lifecycle and expiration policies," 2022.
More… ↓
⤷ Start Trial
|
